Astex Pharmaceuticals, Inc. engages in the discovery and development of small molecule therapeutics with a focus on oncology and hematology using its fragment-based drug discovery platform, Pyramid. The company offers Dacogen (decitabine) for injection for the treatment of patients with myelodysplastic syndrome (MDS). Its product pipeline includes SGI-110, a small molecule DNA-hypomethyating agent that is in Phase I/II trials for treating MDS, acute myeloid leukemia, platinum resistant ovarian cancer, and hepatocellular carcinoma; and AT13387, a small molecule inhibitor of Hsp90, which is in Phase II studies in patients with refractory gastrointestinal stromal tumors, castration resistant prostate cancer, and non-small cell lung cancer. The company’s products also comprise AT7519, a small molecule targeted inhibitor of several cyclin-dependent kinases, which is in Phase II study in combination with bortezomib in patients with multiple myeloma; AT9283, a small molecule inhibitor of kinases, which completed investigation in a Phase II study in a chemotherapy refractory multiple myeloma patient population and pediatric leukemia; and Amuvatinib, a multi-targeted tyrosine kinase inhibitor that completed Phase I study for cancer treatment. In addition, Astex Pharmaceuticals, Inc., together with its partners, engages in developing LEE011, a selective inhibitor of CDK4 and CDK6 in Phase I and Phase I/II clinical trials; AZD5363, an orally active, selective protein kinase B inhibitor in Phase I and Phase I/II clinical trials; JNJ42756493 FGFr inhibitor that is in Phase I clinical trial for cancer treatment; AZD3293, a Phase I clinical trial product for treating Alzheimer’s disease; and AT13148—ACG Kinase Inhibitor that is in Phase I clinical trial. It was formerly known as SuperGen, Inc. and changed its name to Astex Pharmaceuticals, Inc. in September 2011. The company was founded in 1991 and is headquartered in Dublin, California.

Key Statistics